Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03483103 · OUTCOME

The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose after JCAR017 infusion to up to approximately 24 months

What was measured

Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.

Analysis population: All participants who received at least one infusion of JCAR017 who were monitored inpatient

Groups in this outcome

Lisocabtagene Maraleucel (JCAR017)

Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lisocabtagene Maraleucel (JCAR017)41

Reported measurements

Adverse Event
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lisocabtagene Maraleucel (JCAR017)2Not reportedNot reportedNot reportedNot reported
Prophylaxis for CAR T-cell administration
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lisocabtagene Maraleucel (JCAR017)36Not reportedNot reportedNot reportedNot reported
Other
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Lisocabtagene Maraleucel (JCAR017)3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Adverse Event
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        36
    title
    Prophylaxis for CAR T-cell administration
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Other
denoms
  1. counts
    1. group Id
      OG000
      value
      41
    units
    Participants
description
Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.
groups
  1. description
    Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
    id
    OG000
    title
    Lisocabtagene Maraleucel (JCAR017)
param Type
NUMBER
population Description
All participants who received at least one infusion of JCAR017 who were monitored inpatient
reporting Status
POSTED
time Frame
From first dose after JCAR017 infusion to up to approximately 24 months
title
The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice